IP Library Granted Patent US 9,981,949
Granted Patent B2
US 9,981,949 · App. 15/354,832 · Granted May 29, 2018

Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine

Inventors: Srinivasa Rao Akireddy (Winston-Salem, NC); Balwinder Singh Bhatti (Winston-Salem, NC); Timothy J. Cuthbertson (Winston-Salem, NC); Gary Maurice Dull (Lewisville, NC); Craig Harrison Miller (Winston-Salem, NC); Joseph Pike Mitchener, Jr. (Winston-Salem, NC); Julio A. Munoz (Walnut Cove, NC); Pieter Albert Otten (King, NC)
Assignee: Oyster Point Pharma, Inc.
C07D403/06A61K31/4025C07C59/255C07C59/265
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,981,949
App. No.
15/354,832
Granted
May 29, 2018
Kind
B2
Abstract

The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, its salt forms, and novel polymorphic forms of these salts.

Claims (29)

1. A method for manufacture of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine comprising:

(a) treating compound 1

 with methanesulfonyl chloride to give compound 2

(b) treating compound 2 with diethylmalonate and a base selected from the group consisting of potassium tert-butoxide and sodium ethoxide to give compound 3

(c) hydrolyzing compound 3 to give compound 4

(d) decarboxylating compound 4 to give compound 5

(e) reducing compound 5 to give compound 6

(f) treating compound 6 with methanesulfonyl chloride to give compound 7

(g) reacting compound 7 with sodium iodide to give compound 8

 and

(h) treating compound 8 with potassium tert-butoxide to give compound 9, tert-butyl (R)-3-vinylpyrrolidine-1-carboxylate,

2. The method of claim 1 , wherein step (b) does not comprise column chromatography.

3. The method of claim 1 , wherein step (e) does not comprise column chromatography.

4. The method of claim 1 , wherein step (h) does not comprise column chromatography.

5. The method of claim 1 , wherein the hydrolysis of compound 3 is performed by reaction with potassium hydroxide.

6. The method of claim 1 , wherein the decarboxylation of compound 4 is performed in a solvent with heating, and wherein the solvent is selected from the group consisting of water, ethanol, tetrahydrofuran, dimethylformamide, dimethylacetamide, 1,2-dimethoxyethane, dioxane, 1-methyl-2-pyrrolidinone, dimethylsulfoxide, toluene, and mixtures thereof.

7. The method of claim 6 , wherein the solvent for the decarboxylation is selected from 1-methyl-2-pyrrolidinone, dimethylsulfoxide, toluene, and mixtures thereof.

8. The method of claim 1 , wherein the reduction of compound 5 is performed by reaction with a reagent selected from borane, diborane, borane-tetrahydrofuran complex, borane-dimethyl ether complex, and borane-dimethylsulfide complex.

9. The method of claim 8 , wherein the reduction of compound 5 is performed by reaction with borane-tetrahydrofuran complex.

10. The method of claim 1 , further comprising (i) reacting compound 9 with 5-bromo-pyrimidine to give compound 10

11. The method of claim 10 , wherein the reaction of step (i) is a palladium-catalyzed reaction.

12. The method of claim 10 , further comprising (j) deprotecting compound 10 to give compound 11

13. The method of claim 12 , wherein the deprotection reaction of step (j) is performed with a reagent selected from trifluoroacetic acid, hydrochloric acid, and sulfuric acid.

14. A method for manufacture of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate comprising:

(i) mixing the free base, or a solution of the free base, of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine in a first solvent with citric acid in pure form or as a solution of the citric acid in a first solvent to form a citrate salt solution, wherein the first solvent is selected from the group consisting of ethanol, methanol, isopropyl alcohol, isopropyl acetate, acetone, ethyl acetate, toluene, water, methyl ethyl ketone, methyl isobutyl ketone, tert-butyl methyl ether, tetrahydrofuran, dichloromethane, n-heptane, and acetonitrile;

(ii) (a) cooling the resulting citrate salt solution to cause precipitation; or

(ii) (b) adding a second solvent selected from the group consisting of ethanol, methanol, isopropyl alcohol, isopropyl acetate, acetone, ethyl acetate, toluene, water, methyl ethyl ketone, methyl isobutyl ketone, tert-butyl methyl ether, tetrahydrofuran, dichloromethane, n-heptane, and acetonitrile to cause precipitation; or

(ii) (c) evaporating the first solvent and adding a second solvent selected from the group consisting of ethanol, methanol, isopropyl alcohol, isopropyl acetate, acetone, ethyl acetate, toluene, water, methyl ethyl ketone, methyl isobutyl ketone, tert-butyl methyl ether, tetrahydrofuran, dichloromethane, n-heptane, and acetonitrile, and repeating either step (ii) (a) or (ii) (b); and

(iii) filtering to collect the (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine mono-citrate.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Feb 3, 2023
From: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
To: OYSTER POINT PHARMA INC.
Reel/Frame 062582/0873 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE CONVEYING PARTY EXECUTION DATE PREVIOUSLY RECORDED AT REEL: 041044 FRAME: 0211. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 26, 2021
From: TARGACEPT, INC.
To: CATALYST BIOSCIENCES, INC.
Reel/Frame 057923/0518 →
PATENT SECURITY AGREEMENT Recorded Aug 5, 2021
From: OYSTER POINT PHARMA, INC.
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
Reel/Frame 057104/0189 →
CHANGE OF NAME Recorded Jan 13, 2017
From: TARGACEPT, INC.
To: CATALYST BIOSCIENCES, INC.
Reel/Frame 041044/0211 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2017
From: CATALYST BIOSCIENCES, INC.
To: OYSTER POINT PHARMA, INC.
Reel/Frame 041043/0769 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2016
From: AKIREDDY, SRINIVASA RAO; BHATTI, BALWINDER SINGH; CUTHBERTSON, TIMOTHY J.; DULL, GARY MAURICE; MILLER, CRAIG HARRISON; MITCHENER, JOSEPH PIKE, JR.; MUNOZ, JULIO A.; OTTEN, PIETER ALBERT
To: TARGACEPT, INC.
Reel/Frame 040364/0118 →
CHANGE OF NAME Recorded Nov 17, 2016
From: TARGACEPT, INC.
To: CATALYST BIOSCIENCES, INC.
Reel/Frame 040645/0359 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2016
From: CATALYST BIOSCIENCES, INC.
To: OYSTER POINT PHARMA, INC.
Reel/Frame 040645/0282 →
Continuity (5)
Continuation 14832030 · Aug 21, 2015
Continuation 14074147 · Nov 7, 2013
Continuation 13129898
Provisional Application 61118796 · Dec 1, 2008
Related Publication 20170260167A1 · Sep 14, 2017